BIO

·  Unique combination of skills:

   Scientist – Entrepreneur – Chief Executive – Art - Music

·  Founder, Chairman, CEO - Six Biotechnology Companies

·  Polymath - Creative Problem Solver

·  Capitol Hill experience

·  Raised $91 million in funding

·  Accomplished Public Speaker

·  Music composition & Painting - complement Science and Business

·  Inventor on Seven Patents

·  Technical background in Biochemistry, Molecular Biology, Cytokines, Taxol, Monoclonal Antibodies, Gene Regulation, Hemoglobin, Oncology, Alzheimer’s Disease, Aging/Longevity

·  Closed University Licensing agreements with UCLA, Univ. California-San Diego, Washington State, Montana State, University of Texas at Dallas, Texas Tech University, University of British Columbia, MD Anderson Cancer Center, University of Texas Southwestern Medical School

·  Closed Business Transactions: Bristol Myers Squibb, MERCK, Phillips Petroleum Biotechnology Division, Nuron Biotech

Professional Experience

Allosteric Bioscience, Inc. – Co-Founder, President, Director

2021 – Present

-   Focus on Creation of New, Highly Effective, Medical Treatments for Optimization of Aging/ Longevity and Aging related diseases

- using Quantum Computers and Advanced Artificial Intelligence integrated with disciplines and databases of, Genetics, Systems Biology, Genomics, Epigenetics, Proteomics and Computer Based Drug Design – Related to previous work with John Pople who received the Nobel Prize for quantum chemistry as described below

- ABI 11 lead target - in normal Aging and genetic diseases of Aging.

- In 2025 licensed technology for prevention and treatment of Sarcopenia (muscle wasting – due to normal aging and use of weight loss and diabetes drugs and diseases like cancer and ALS) from Johns Hopkins University.

VITRUVIAN BioMedical, Inc., Founder, Chairman & CEO

 2010 - Present         

-        Focus on Alzheimer’s Disease Optimized prevention and treatment

-        Global Exclusive License to Alzheimer’s Disease DNA Vaccine targeting all key proteins, Abeta, TAU, and pTAU – novel strategy has potential to be most effective Prevention and Treatment

-        Alzheimer Disease Blood Test – targeting proprietary biomarker

SignPath Pharma, Inc. - Co-Founder, former Chairman - Board of Directors 2006- Present

-        Focus on Liposome-Curcumin (LipoCurc) treatment of cancer     

-        Licensed technology from MD Anderson Cancer Center

-        Phase I a, b Clinical Trial completion – no significant toxicity Initial Phase II clinical trials show no regressions in treatment of glioblastoma at Johns Hopkins Medical Center

-        CORREQT – prevention of QT prolongation cardiotoxicity

HemoBioTech, Inc., Former Chairman, President & CEO - 2003-2010

-        Focused on HemoTech - a red blood cell substitute, licensed from Texas Tech University.  HemoTech is a bovine hemoglobin modified and polymerized with Adenosine, ATP and GSH.

Cytoclonal Pharmaceutics, Founder, Chairman, CEO, 1992 - 2001

-        Business agreement with Bristol Meyers Squibb for Taxol production - using fungal fermentation

-        Continuation of Wadley Biosciences/LPL technology (below)

-        Acquisition of drug design technology based on Nobel Prize work of Dr. John Pople who served as Scientific Advisor

-        Cancer diagnostic technology using DNA probes and Monoclonal Antibodies Imaging

-        Raised $65 million including IPO in 1995

-        Licensing agreements with UCLA, UC- San Diego, WSU, Montana State University for fungal fermentation for Taxol production, University of Texas at Dallas for anti-sense technology

-        Was merged to form OPKO Health, Inc, (OPK - NASDAQ – market cap approximately $1.4 billion)

Wadley Biosciences/LPL, Founder, Chairman & CEO - 1987- 1992

-        Established Venture between Phillips Petroleum Biotechnology Division and Wadley Cancer Center

-        Major focus on Cytokine technology for cancer treatment – Interferon/Tumor Necrosis factor genes cloned and expressed in proprietary fermentation technologies – TNF Phase II clinical trials

-        Additional focus on Monoclonal Antibodies (MAbs) for non-small cell lung cancer imaging and diagnosis – clinical imaging trials

-        P. pastoris fermentation – Phillips Petroleum

-        Microbial fermentation – E. coli and S. cereviseae  - Wadley

-        Microbial transport systems – yeast proprietary technology

-        Select technologies served as basis for Cytoclonal Pharmaceutics

Wadley Institutes of Molecular Medicine, Chairman of Department of Molecular Genetics and Director of Genetic Engineering - 1979 - 1987

-        Focus on cytokine technology for cancer treatment

-        Tumor Necrosis Factor:  cloning, production, Phase I clinical trial

-        Also focus on MAbs for cancer diagnosis and treatment

-        Research on gene regulation in human cells and yeast

University of Texas at Dallas - Adjunct Professor - 1983 - 1989

University of Texas Southwestern Medical School - Assistant Professor Department of Biochemistry- 1972- 1979

-        Research focus on gene regulation in yeast and animal cells

Education

Doctor of Philosophy - Rutgers University - 1970

(Mentor - Dr. Henry Vogel – defined repression of enzyme synthesis - Epigenetics) 

Postdoctoral Fellow   - Yale University       - 1970 – 1972

(Transitioned from gene regulation in E.Coli to gene regulation in Saccharomyces cerevisiae)

Select Communications, Presentations

1)    Longevity Technology – “Longevity drug discovery harnesses the power of the quantum computing”, interview, March 10, 2022

2)    Bollon, A.P., “DNA Vaccine Strategies for Alzheimer’s Disease”, Meridian Clinical Trials Summit”, 2020, invited speaker

3)    Bollon, A.P., “Alzheimer’s Disease DNA Vaccine Targeting ABeta, TAU and pTAU”, Biotech Showcase, San Francisco, CA., 2018

4)    Bollon, AP, “VITRUVIAN BioMedical Licenses New Alzheimer’s Vaccine Targeting ABeta + TAU”, Business Wire, October 4, 2017.

5)    Bollon,AP, “Biomarker and Vaccine Strategies for Alzheimer’s Disease”, invited speaker, 4 th International Conference on Neurology and Neuroimmunology, September 18-19, 2017.

6)    Powers, M. “VITRUVIAN Seeking a Balance of Therapeutics, Diagnostics,” BIOWORLD TODAY. 2012:23, 1-8

7)    Miller D, Selbovitz M, Bollon AP. “Need for Blood Substitute to Prevent HIV Transmission,” 5^th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2010.

8)    Dejong JM, Liu Y, Bollon AP, Long RM, Jennewein S, Williams D, Croteau RB. “Genetic engineering of Taxol biosynthetic genes in Saccharomyces cerevisiae,” Biotechnology and Bioengineering. 2006; 93, 212-224.

9)    Hall C. “Bridging Worlds,” Dallas Morning News.  February 7, 1999. (Arthur P. Bollon and Cytoclonal Pharmaceutics).

10) Sidh, R.S., and Bollon. A.B., “Tumor Necrosis Factor Analogs: Identification of Functional Domains,” Anticancer Research,

9:1569-1576.

11) Bollon AP, Berent S, Torczynski R, Hill N, Jia FL, Joher A, Pichyangkul, S, Khan A, “Human Cytokines, Tumor Necrosis Factor and Interferons: Gene Cloning, Animal Studies and

Clinical Trials,” Journal of Cellular Biochemistry. 1988; 36, 353-367.

12) Torczynaski, R., Fuke, M. and Bollon, A.B., “Human Genomic Library Screened with 17-Base Probes Yields a Novel Interferon”, “Proc. Natl. Acad. Sci., 81, 6451-6466, (1984)

13) Bollon, A.B., Barron, E.A., Berent, S.L., Bragg, P.W., Dixon, D., Fuke., M., Hendrix,C., Mahmoudi,M., Sidhu,R.S., and Torczynski,R. “Recominant DNA Techniques: Isolation, Cloning, and Expression of Genes,” (in “Recombinant DNA Products: Insulin Interferon and Growth Hormone,” edited by A.P. Bollon, CRC Press, Boca Rotan, FL) pp. 1-35 (1984)

A list of 47 Scientific Publications available on request.

Other Interests

1)              Martial Arts: Shorin-Ryu Karate - 4^th degree black belt - Sensai (teacher).  

2)              Art: Uncle Robert Skalka was accomplished water colorist and introduced me to painting prior to high school. In college I minored in Art and studied with major artists Jules Olitski and Gillian Jagger.

Taught painting at Yale University, Trumbull College while doing a Postdoctoral Fellowship in medical research at the Yale Medical School.  Exhibited art in New York City, Columbia University, New Brunswick, Yale, Orange County, California and Dallas.

3)              Music: Uncle Joseph Bollon was an accomplished pianist and composer and introduced me to piano and music composition prior to high school. Studied music with music pioneer Stefan Wolpe and music composition with Robert Rodriguez and piano with Jo Boatright.

Performed original piano composition dedicated to 9/11 at Remembrance of 9/11 in 2014 and in Dallas in 2015. Cited as “Beautiful and Moving” by lead pianist of the Dallas Symphony Orchestra. Work was composed after returning to Dallas from New York City after 9/11.  

Chair of Gala for Dallas Chamber Music Society concert by The Academy of St. Martin in the Fields Chamber Ensemble.  I presented an installation of my Art, Music and Video, at the Gala in 2015.

Performance of original, piano compositions at a private Gala in Dallas and other public occasions.

4)              Non-Profit Boards:

Past President and Board of Directors of Voices of Change: Contemporary music ensemble in Dallas

Former Board of Directors of TITAS:  Dallas arts organization presenting leading dance companies from around the world  

Former Director of the Board of Directors of Dallas Chamber Music Society which presents leading chamber music ensembles from around the world